Please login to the form below

Not currently logged in
Email:
Password:

AML

This page shows the latest AML news and features for those working in and with pharma, biotech and healthcare.

Roche keeps Venclexta train rolling with new leukaemia filing

Roche keeps Venclexta train rolling with new leukaemia filing

Roche keeps Venclexta train rolling with new leukaemia filing. The drug could treat AML patients who are ineligible for chemotherapy. ... 2024, providing it can also pick up approvals in AML and other indications like multiple myeloma.

Latest news

More from news
Approximately 9 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Digital disruption Digital disruption

    Initially AZ and Microsoft have focused acute myeloid leukaemia (AML), simulating experiments to predict how drug combinations might be used to overcome resistance to drugs that target cell signalling in AML,

  • Deal Watch December 2016 Deal Watch December 2016

    790. Tolero Pharma (US). Dainippon Sumitomo (Japan). Acquisition with milestones. Portfolio, including alvocidib, a CDK9 inhibitor with phase II completed in AML.

  • Deal Watch July 2016 Deal Watch July 2016

    Earlier this year Jazz completed its acquisition of Celator Pharmaceuticals, acquiring a late-stage product, Vyxeos, which targets AML, and the new agreement brings complementary products to Jazz's portfolio.

  • Deal Watch June 2016 Deal Watch June 2016

    Paying $150m upfront Novartis gains access to XmAb14045 being developed for acute myeloid leukaemia (AML) and XmAb13676 in development for B-cell malignancies. ... 2 T-cell engaging XmAb bispecific antibodies: XmAb14045 for AML and XmAb13676 for B-cell

  • Deal Watch May 2016 Deal Watch May 2016

    2, 000. Celator/ Jazz. Corporate acquisition. Acquisition for $30.25 per share brings Vyxeos [nano scale liposomal formulation of cytarabine /daunorubicin] for AML, completed P3.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Actinium appoints director of clinical operations Actinium appoints director of clinical operations

    Greg's direct experience in AML and significant knowledge of clinical trial management will have an immediate impact on our capabilities that we expect will add efficiency and scale to our

  • Celgene promotes Karen Browne to haematology director Celgene promotes Karen Browne to haematology director

    She then relocated to Switzerland in March 2010, taking up the role of associate director of MDS and acute myeloid leukaemia (AML), and less than two years later was promoted to ... director with responsibility for overall MDS/AML marketing across Europe.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics